thenewsbit.com

Category: Medical

  • Centre rolls out free 7-day treatment for accident victims

    Centre rolls out free 7-day treatment for accident victims

    Union Minister for Road Transport and Highways Nitin Gadkari announced that the government is working on a new measure to provide free medical treatment for road accident victims. Under the proposed initiative, anyone admitted to a hospital after an accident will be eligible for free treatment for up to seven days.

    Currently, road accident victims are eligible for compensation under the Motor Vehicles Act and can access limited support through schemes such as the Solatium Fund. In recent years, the government has also introduced pilot projects for cashless treatment along National Highways, supported by the National Highways Authority of India (NHAI). However, large parts of the country continue to lack a uniform, nationwide system for immediate and comprehensive medical care.

    India continues to grapple with the grim distinction of being the world’s road accident capital. According to official data, the country records over 4.6 lakh road crashes annually, resulting in nearly 1.6 lakh deaths and more than 4 lakh injuries. On average, 18 lives are lost every hour due to road accidents. Two-wheelers account for the highest share of fatalities, followed by pedestrians and cyclists.

    Despite several interventions, including the amended Motor Vehicles Act and stricter enforcement of traffic rules, post-accident trauma care remains a weak link. Experts note that the first hour after an accident — the “golden hour” — is critical, and lack of immediate medical attention is a leading cause of preventable deaths.

    Gadkari made the announcement while addressing the 65th Annual Convention of the Society of Indian Automobile Manufacturers (SIAM), held at Hotel Taj Palace, New Delhi. The convention brings together senior government officials, global and domestic auto industry leaders, policymakers, and experts to discuss the future of mobility and India’s role in the global transition toward sustainable and software-driven vehicles.

    The minister’s statement is seen as part of the government’s broader efforts to enhance road safety and strengthen post-accident care infrastructure in the country. Autocar Professional

  • Burning Rock achieves 9.6% revenue growth in Q2 2025

    Burning Rock achieves 9.6% revenue growth in Q2 2025

    Burning Rock Biotech Limited, a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2025.

    Second Quarter 2025 Financial Results
    Total Revenues were RMB148.5 million (US$20.7 million) for the three months ended June 30, 2025, representing a 9.6% increase from RMB135.5 million for the same period in 2024.

    • Revenue generated from in-hospital business was RMB62.5 million (US$8.7 million) for the three months ended June 30, 2025, representing a 4.4% increase from RMB59.9 million for the same period in 2024, driven by an increase in sales volume from existing hospitals and new contracted partner hospitals.
    • Revenue generated from central laboratory business was RMB40.9 million (US$5.7 million) for the three months ended June 30, 2025, representing a 16.2% decrease from RMB48.8 million for the same period in 2024, primarily attributable to a decrease in the number of tests, as we continued our transition towards in-hospital testing.
    • Revenue generated from pharma research and development services was RMB45.2 million (US$6.3 million) for the three months ended June 30, 2025, representing a 68.1% increase from RMB26.9 million for the same period in 2024, primarily attributable to an increased development and testing services performed for our pharma customers.

    Cost of revenues was RMB40.5 million (US$5.6 million) for the three months ended June 30, 2025, representing an 0.9% increase from RMB40.1 million for the same period in 2024.

    Gross profit was RMB108.1 million (US$15.1 million) for the three months ended June 30, 2025, representing a 13.3% increase from RMB 95.4 million for the same period in 2024. Gross margin was 72.8% for the three months ended June 30, 2025, compared to 70.4% for the same period in 2024. By channel, gross margin of central laboratory business was 87.9% for the three months ended June 30, 2025, compared to 78.8% during the same period in 2024, primarily due to a reduction in material and shipping costs resulted from cost optimization and control measures; gross margin of in-hospital business was 74.4% for the three months ended June 30, 2025, compared to 73.6% during the same period in 2024, primarily due to a decreased depreciation; gross margin of pharma research and development services was 56.8% for the three months ended June 30, 2025, compared to 48.2% during the same period of 2024, primarily due to a decreased depreciation and an increase in test volume of higher margin projects.

    Non-GAAP gross profit, which excludes depreciation and amortization expenses, was RMB110.5 million (US$15.4 million) for the three months ended June 30, 2025, representing a 8.4% increase from RMB101.9 million for the same period in 2024. Non-GAAP gross margin was 74.4% for the three months ended June 30, 2025, compared to 75.2% for the same period in 2024.

    Operating expenses were RMB119.6 million (US$16.7 million) for the three months ended June 30, 2025, representing a 42.1% decrease from RMB206.7 million for the same period in 2024. The decrease was primarily driven by budget control measures and headcount reduction to improve the Company’s operating efficiency.

    • Research and development expenses were RMB49.8 million (US$6.9 million) for the three months ended June 30, 2025, representing a 23.4% decrease from RMB65.0 million for the same period in 2024, primarily due to (i) a decrease in amortized expense on share-based compensation; and (ii) a decrease in the expenditure for research projects.
    • Selling and marketing expenses were RMB38.4 million (US$5.4 million) for the three months ended June 30, 2025, representing a 21.5% decrease from RMB48.9 million for the same period in 2024, primarily due to (i) a decrease in staff cost resulted from the reorganization of the sales department and improvement in operating efficiency; and (ii) a decrease in entertainment expense; and (iii) a decrease in depreciation and amortization expense.
    • General and administrative expenses were RMB31.4 million (US$4.4 million) for the three months ended June 30, 2025, representing a 66.1% decrease from RMB92.8 million for the same period in 2024, primarily due to an decrease in amortized expense on share-based compensation.

    Net loss was RMB9.7 million (US$1.4 million) for the three months ended June 30, 2025, compared to RMB108.0 million for the same period in 2024.

    Cash, cash equivalents and restricted cash were RMB455.0 million (US$63.5 million) as of June 30, 2025.

    Exchange Rate Information
    This press release contains translations of certain Renminbi amounts into U.S. dollars at a specified rate solely for the convenience of the reader. Unless otherwise noted, all translations from Renminbi to U.S. dollars and from U.S. dollars to Renminbi are made at a rate of RMB7.1636 to US$1.00, the exchange rate on June 30, 2025, set forth in the H.10 statistical release of the Federal Reserve Board. The Company makes no representation that the Renminbi or U.S. dollars amounts referred could be converted into U.S. dollars or Renminbi, as the case may be, at any particular rate or at all.
    The NewsBit Bureau

  • EU Healthcare faces €23B cost from disposable items

    EU Healthcare faces €23B cost from disposable items

    The A Prescription for Change report estimated that the sector’s dependence on disposable items such as gloves, fluid bags and packaging created around five million tonnes of carbon dioxide equivalent emissions and cost health providers €23 billion.

    Without action, the report warned that annual costs could rise to over €34 billion by 2040, while plastic waste volumes and associated emissions continue to climb.

    Cutting single-use plastics by half
    The report identified seven high-volume plastic categories as the main culprits: fluid bags and tubing, gloves, rigid devices, device packaging, personal protective equipment (PPE), wipes and pharmaceutical packaging.

    A combination of economic, regulatory and demographic factors were pinpointed as driving up healthcare’s reliance on single-use plastics.

    Notably, virgin plastic remains cheaper than recycled or alternative materials, making it the default choice in cost-sensitive health systems.

    Strict safety standards and regulatory exemptions have also reinforced disposables as standard practice.

    To tackle this impact, Eunomia and Systemiq recommended:

    • Reduce unnecessary use (e.g. overuse of gloves)
    • Reuse safe, durable alternatives such as gowns, trays and masks
    • Where safe to do so, substitute with paper-based or compostable materials
    • Improve recycling through better design and segregation
    • Procure low-GHG emissions plastics from biobased or Carbon Capture and Storage (CCS)-derived sources

    According to the report, applying these levers at scale could cut single-use plastic use in healthcare by over 50%.

    Will Clark, International Supply Chain Transformation Director at Health Care Without Harm, commented: “Protecting patient health is non-negotiable – but many plastics pose their own risks.

    “This report shows we can safely reduce or replace plastics, cut costs and environmental harm and still deliver high-quality care.”

    Schemes to reduce plastics already underway
    In England, NHS trusts have switched from disposable to reusable surgical trays, eliminating thousands of single-use plastic items each year.

    The government has also introduced legislation to restrict the sale and supply of plastic-containing wet wipes, although the ban will not include the manufacture of these products.

    Pallavi Madakasira, Managing Consultant at Eunomia, said: “This report presents the strongest evidence yet to galvanize the global healthcare community into urgent action on plastic waste.

    “It offers a common set of priority interventions and a data-driven roadmap to accelerate progress. Most importantly, it shows that safe, proven and cost-saving solutions are already within reach.”

    Mahmood Bhutta, Chair of ENT Surgery at Brighton and Sussex Medical School, Director of the Green Healthcare Hub and a surgeon in the NHS, added: “The volume of disposable materials used in healthcare, including plastic, is staggering.

    “Across Europe, hospitals are already showing that reusables and smarter product design can cut costs, carbon emissions and plastics use – without compromising patient safety.”

    Healthcare needs ‘wiser management of plastic’
    The report noted that while regulators have tightened packaging and waste laws across Europe, medical plastics frequently remain outside their scope due to patient safety concerns.

    But with public health budgets under strain and climate targets looming, pressure is mounting on governments and providers to act.

    Health Care Without Harm, a global NGO, coordinated an open letter endorsed by more than 48 million healthcare professionals in 2024, urging a phase-out of harmful plastics in healthcare.

    In October 2024, Secretary for Health and Social Care Wes Streeting announced a new strategy to cut down on the number of single-use medical devices used by the NHS by reducing its reliance on foreign imports and encouraging local innovation and reuse.

    Eunomia and Systemiq argued that combining procurement reform, regulatory updates and investment in reuse and recycling infrastructure can turn fragmented pilots into a coordinated strategy.

    Yoni Shiran, Partner and Plastics Lead at Systemiq, said: “By redesigning products and procurement around circular economy principles, we can protect patients, protect budgets, and build resilience against future shocks.

    “At a time where public budgets are under huge pressure, a wiser management of plastic in healthcare presents an opportunity to use public spending more efficiently.” Letsrecycle

  • Q2 2025: Shoulder Innovations posts $11M revenue, up 33%

    Q2 2025: Shoulder Innovations posts $11M revenue, up 33%

    Shoulder Innovations, Inc., a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today reported financial results for the second quarter ended June 30, 2025.

    Recent Business Highlights

    • Increased net revenue 33% year-over-year to $11.0 million in the second quarter of 2025, in-line with the range provided in the company’s Registration Statement
    • Achieved gross margin of 76.2% in the second quarter of 2025
    • Sold 1,503 total implant systems in the second quarter of 2025, a 34% increase year-over-year
    • Closed a $40 million convertible notes financing
    • Completed an initial public offering (IPO), raising $75 million of gross proceeds
    • Appointed Rick Buchholz to its Board of Directors
    • Expanded I-Series humeral stem product line with the full commercial launch of the InSet™ 70

    “We are pleased with both our second quarter performance, which was in-line with the preliminary estimates, and the momentum in our business,” said Rob Ball, CEO of Shoulder Innovations. “Our financial results and operational progress reflect accelerating market adoption of our advanced implant systems for anatomic and reverse total shoulder arthroplasty. Additionally, we are expanding our base of surgeon customers, which increased nearly 50% year-over-year in the second quarter.”

    “From a balance sheet perspective, we are also excited to have successfully completed our convertible notes financing and IPO and are grateful for the support of all the investors who participated,” Mr. Ball continued. “With these financings, we are well- positioned to continue scaling our investments to execute on our growth strategies. We look forward to further advancing our mission of transforming shoulder arthroplasty and our efforts to enable best-in-class outcomes for shoulder specialists and their patients and create long-term shareholder value.”

    Second Quarter 2025 Financial Results
    Net revenue in the second quarter of 2025 increased 33% to $11.0 million, compared to $8.3 million in the second quarter of 2024. The increase was due to an increase in the number of implant systems sold, as well as an increase in the number of new customers.

    Gross margin in the second quarter of 2025 was 76.2%, compared to 76.9% in the second quarter of 2024.

    Selling, general, and administrative expenses in the second quarter of 2025 increased 40% to $12.8 million, compared to $9.2 million in the second quarter of 2024. The increase was primarily due to increased headcount in the commercial organization, higher legal costs related to litigation, and increased legal, accounting, and professional service fees related to the transition to a public company.

    Research and development expenses in the second quarter of 2025 increased 21% to $1.4 million, compared to $1.2 million in the second quarter of 2024. The increase was due to investment in new product development efforts.

    Operating loss in the second quarter of 2025 was $5.9 million, compared to a loss of $4.0 million in the second quarter of 2024.

    Net loss in the second quarter of 2025 was $19.2 million, compared to a net loss of $4.2 million in the second quarter of 2024. The increase was primarily related to a $13.1 million expense for changes in the fair value of the company’s preferred stock warrant liability and Series E purchase option.

    Adjusted EBITDA in the second quarter of 2025 was a loss of $18.1 million, compared to a loss of $3.2 million in the second quarter of 2024. The increase in loss was primarily due to the aforementioned changes in the fair value of the company’s preferred stock warrant liability and Series E purchase option.

    As of June 30, 2025, cash, cash equivalents, and marketable securities totaled $39.6 million. The company received an aggregate of approximately $115 million of gross proceeds from the issuance of its convertible notes in July 2025 and its IPO, which closed on August 1, 2025.

    2025 Financial Outlook
    Shoulder Innovations expects revenue for the full year 2025 to be in the range of $42 million to $44 million, representing growth of approximately 33% to 39% over full year 2024 revenue.

    Morgan Stanley 23rd Annual Global Healthcare Conference
    Members of management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference today, September 9, 2025, at 8:30 a.m. ET. A live and archived webcast of the fireside chat will be available on the “Investor Relations” section of the Shoulder Innovations website at https://ir.shoulderinnovations.com/.

    Use of Non-GAAP Financial Measures and Key Business Metrics
    In addition to our results and measures of performance determined in accordance with U.S. GAAP, we believe that non-GAAP financial measures can be useful in evaluating and comparing our financial and operational performance over multiple periods, identifying trends affecting our business, formulating business plans and making strategic decisions. We use and present Adjusted EBITDA for this purpose. We define Adjusted EBITDA as net loss before interest expense, net, income tax expense, depreciation and amortization, stock-based compensation expense.

    We believe that Adjusted EBITDA, together with a reconciliation to net loss, provides meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our business, results of operations, or outlook. However, Adjusted EBITDA has limitations as an analytical tool, and you should not consider this measure in isolation or as a substitute for analysis of our financial results as reported under U.S. GAAP. Some of these potential limitations include: other companies, including companies in our industry which have similar business arrangements, may report Adjusted EBITDA, or similarly titled measures but calculate them differently, which reduces their usefulness as comparative measures; although depreciation and amortization expenses are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and Adjusted EBITDA does not reflect cash capital expenditures for such replacements or for new capital expenditure requirements; Adjusted EBITDA also does not reflect changes in, or cash requirements for, our working capital needs or the potentially dilutive impact of stock- based compensation; and Adjusted EBITDA does not reflect the interest expense, or the cash requirements necessary to service interest or principal payments, on existing or future debt that we may incur. Because of these and other limitations, you should consider Adjusted EBITDA only as supplemental to other GAAP-based financial measures.

    In addition, we believe that the number of implant systems sold is a key business metric and a useful indicator of our ability to drive demand for our implant systems, generate net revenue and expand our business. We regularly review a number of operating and financial metrics to evaluate our business, measure our performance, identify trends affecting our business, formulate our business plan and make strategic decisions.
    The NewsBit Bureau

  • Medical Tourism in India surges with six cities at the forefront

    Medical Tourism in India surges with six cities at the forefront

    India is rapidly emerging as a leading global destination for medical tourism in 2025, with a surge in medical tourists seeking affordable, high-quality healthcare services. Key cities including Delhi, Bangalore, Mumbai, Chennai, Hyderabad, and Goa are at the forefront of this growth, offering world-class medical facilities and comprehensive care packages to international patients. Over 1.31 lakh foreign medical tourists arrived in India between January and April 2025, marking a significant increase fueled by cost advantages, government initiatives, and expanding insurance options. With specialized treatments spanning elective surgeries, organ transplants, fertility treatments, and wellness therapies, India is transforming the medical tourism landscape with its blend of affordability, expertise, and cultural familiarity.

    Introduction: India’s Ascendancy as a Medical Tourism Powerhouse
    India’s medical tourism industry is experiencing a remarkable renaissance, becoming a top choice for global patients seeking quality care at accessible prices. Leading metropolitan hubs—Delhi, Bangalore, Mumbai, Chennai, Hyderabad, and emerging wellness-rich Gujarat and Goa—are driving this trend with internationally accredited hospitals, cutting-edge technologies, and renowned medical experts. The Indian government’s proactive policies, including the ‘Heal in India’ campaign and streamlined e-medical visa facilities, have further simplified access for foreign patients.

    Medical tourists are drawn to India’s unbeatable cost savings: complex surgeries that range from $20,000 to $40,000 globally are available for fractions of that cost, with high-volume elective procedures priced between $2,000 and $15,000. Moreover, India’s robust health insurance offerings have become more affordable, enabling easier coverage for both residents and NRIs seeking treatment domestically. Hospitals provide end-to-end care packages including visa assistance, travel arrangements, and post-operative follow-up, enabling patients to focus solely on recovery in a supportive environment.

    Patients value India’s blending of advanced medical science with traditional healing modalities such as Ayurveda and Yoga, which deliver holistic wellness alongside modern treatments. This comprehensive appeal drives not only an influx of international patients but also growing confidence in India as a global healthcare destination poised for continued expansion. This report delves into the multifaceted drivers behind India’s medical tourism boom, spotlighting destination highlights, government programs, cost benefits, insurance landscape, and growth projections shaping this dynamic sector.

    Leading Medical Tourism Destinations in India

    • Delhi: Renowned for specialized oncology, cardiology, and neurology treatments in world-class tertiary hospitals.
    • Bangalore: Recognized as a biotech and surgical innovation hub offering affordable advanced procedures.
    • Mumbai: Home to premier private hospitals delivering comprehensive, multi-specialty care.
    • Chennai: South India’s healthcare nucleus, excelling in cardiac surgeries and fertility treatments.
    • Hyderabad: Growing prominence in organ transplantation and internationally accredited medical centers.
    • Gujarat: Known for integrated wellness resorts combining modern care and traditional therapies.
    • Goa: Rising wellness and post-operative recuperation destination with expanding medical tourism support.

    Cost Advantages Driving Influx
    India’s medical procedures are considerably more affordable than in Western markets, making it a preferred option for cost-conscious patients worldwide.

    • Elective surgeries cost between $2,000 and $15,000.
    • Complex procedures including heart surgeries and organ transplants range from $20,000 to $40,000.
    • Example: Coronary artery bypass surgery costs $8,000-$10,000 in India versus $100,000+ in the US.
    • Economical generic medicines support chronic disease management and long-term care affordability.

    Increasing Availability and Affordability of Insurance
    Health insurance premiums in India are notably low, typically ranging from $120 to $300 annually, encouraging broader adoption.

    • Many insurance plans now cover support services for NRIs managing elderly parental care domestically.
    • Growing insurance sectors enhance patient financial security and long-term treatment feasibility.

    Government Support and Policy Initiatives

    • Simplified e-medical visa and attendant visa schemes for nationals of 171 countries, facilitating easier entry.
    • ‘Heal in India’ campaign promoting synergies among healthcare providers, airlines, and hospitality sectors.
    • State-level programs encouraging wellness tourism, skill development, and patient experience enhancement.
    • Incentives and accreditation benchmarks to boost global standards and patient safety.

    Surging Demand and Market Outlook

    • 1,31,856 foreign medical tourist arrivals reported January-April 2025; 4.1% of total foreign arrivals.
    • Annual medical tourist arrivals increased to over 6.4 lakh in 2024, from 1.82 lakh in 2020.
    • Projected growth to a $58.2 billion industry by 2035 with a compound annual growth rate (CAGR) of 12.3%.
    • High demand for specialized care such as cosmetic surgery, fertility treatment, orthopedics, and transplants.

    Additional Drivers for Medical Tourism Popularity

    • Comfortable cultural familiarity and English-speaking healthcare providers.
    • End-to-end hospital packages including visa, travel, accommodation, and post-treatment care.
    • Integration of holistic medical systems like Ayurveda and Yoga with cutting-edge technology.
    • Strong familial support networks aiding emotional and physical recovery.

    Strategic Role of Medical Cities

    • Delhi and Mumbai cater to advanced surgeries and diagnostics.
    • Bangalore leads in biotech research and innovative surgical solutions.
    • Chennai and Hyderabad boast high-quality accredited hospitals with surgical specialties.
    • Gujarat and Goa complement medical tourism with wellness retreats and recovery centers.

    Conclusion
    India’s medical tourism sector is witnessing unprecedented growth, driven by an unbeatable value proposition of world-class healthcare at accessible costs. With government backing, expanding insurance coverage, and leading healthcare metros, India is set to solidify its position as a global medical tourism hub. Patients from around the world are increasingly prioritizing India for both routine and complex medical treatments, supported by cultural comfort and comprehensive care solutions. The country’s medical tourism ecosystem is well poised for continued robust growth, offering an unmatched combination of quality, affordability, and holistic wellness. Travel And Tour World

  • Sahajanand Medical submits DRHP for IPO with SEBI

    Sahajanand Medical submits DRHP for IPO with SEBI

    The Indian stock market is abuzz with anticipation as Sahajanand Medical Technologies, a prominent player in the medical devices sector and a favorite among ace investor Ashish Kacholia, has officially filed its Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (SEBI). This significant move signals the company’s intent to go public and raise substantial funds, marking a potentially transformative chapter for the Ahmedabad-based firm. The upcoming Sahajanand Medical Technologies IPO is poised to be one of the most closely watched Indian IPOs in recent times, especially given its strong backing and its strategic position within the rapidly expanding medical devices market in India.

    Ashish Kacholia’s Strategic Investment in Medical Devices
    Renowned investor Ashish Kacholia, known for his keen eye for identifying high-growth potential companies in the small and mid-cap space, has a significant stake in Sahajanand Medical Technologies. His endorsement lends considerable weight to the company’s prospects and has already generated considerable interest from the investment community. Kacholia’s philosophy often centers on backing businesses with robust fundamentals, strong management teams, and a clear path to market leadership. Sahajanand Medical Technologies, with its innovative product portfolio and ambitious expansion plans, appears to fit this mold perfectly. Investors are keenly observing Ashish Kacholia’s portfolio for insights, and this IPO news is a major development for his followers.

    Sahajanand Medical Technologies: A Pioneer in Cardiovascular Solutions
    Founded in 2004, Sahajanand Medical Technologies has carved a niche for itself as a leading manufacturer of cardiovascular devices, particularly in the critical area of cardiac stents. The company is recognized for its vertically integrated business model, which encompasses research and development, manufacturing, and marketing of a diverse range of medical equipment. Their product suite includes:

    • Drug-Eluting Stents (DES): Essential for preventing re-narrowing of arteries after angioplasty.
    • Balloons and Catheters: Key tools for minimally invasive procedures.
    • Other Interventional Cardiology Devices: Addressing a broad spectrum of cardiovascular interventions.

    The Sahajanand Medical Technologies business model emphasizes innovation and quality, aiming to provide cost-effective and advanced treatment options for patients. This focus on critical healthcare needs positions them favorably in a market driven by increasing healthcare expenditure and a growing demand for sophisticated medical solutions.

    The Purpose of the IPO: Fueling Expansion and Innovation
    The funds raised through the upcoming IPO will be strategically deployed to fuel Sahajanand Medical Technologies’ growth trajectory. While the exact issue size and price band are yet to be determined, the DRHP filing indicates a clear intention to capitalize on market opportunities. Key objectives for fund utilization are expected to include:

    • Capacity Expansion: Scaling up manufacturing facilities to meet growing domestic and international demand.
    • Research and Development (R&D): Investing in the development of next-generation medical devices and innovative technologies.
    • Market Penetration: Strengthening their presence in existing markets and exploring new geographical territories.
    • Working Capital Requirements: Ensuring smooth operational flow and supporting day-to-day business activities.

    This fundraising initiative underscores the company’s ambition to solidify its leadership position in the Indian medical devices sector and expand its global footprint.

    Navigating the Indian Medical Devices Landscape
    The Indian medical devices market is experiencing a significant upswing, driven by several key factors:

    • Increasing Healthcare Spend: Government initiatives and rising disposable incomes are leading to higher healthcare expenditures.
    • Growing Patient Demographics: A large and aging population necessitates greater access to advanced medical treatments.
    • Government Support: Initiatives like “Make in India” and Production Linked Incentive (PLI) schemes are encouraging domestic manufacturing.
    • Technological Advancements: The adoption of cutting-edge technologies is enhancing the efficacy and accessibility of medical devices.

    Sahajanand Medical Technologies is well-positioned to capitalize on these trends. Their expertise in cardiovascular devices, coupled with their focus on indigenous manufacturing, aligns perfectly with the nation’s healthcare goals. The medical technology industry in India is ripe for growth, and companies like Sahajanand are at the forefront of this revolution.

    Key Strengths and Competitive Advantages
    Sahajanand Medical Technologies boasts several strengths that are likely to appeal to potential investors in the upcoming IPO:

    • Strong Product Portfolio: A comprehensive range of high-quality cardiovascular devices.
    • Vertical Integration: Control over the entire value chain from R&D to manufacturing.
    • Established Distribution Network: A robust presence in both domestic and international markets.
    • Experienced Management Team: Led by seasoned professionals with deep industry knowledge.
    • Favorable Market Dynamics: Operating in a high-growth sector with increasing demand.
    • Investor Confidence: Backing from prominent investors like Ashish Kacholia.

    These factors contribute to a compelling investment thesis for the Sahajanand Medical Technologies share sale.

    The IPO Process and What Investors Should Watch For
    The filing of the DRHP is the first step in the IPO process. This document provides a detailed overview of the company’s financials, business operations, risks, and management. Following SEBI’s review and approval, Sahajanand Medical Technologies will proceed with the Red Herring Prospectus (RHP), which will contain the final details of the issue, including the IPO price band and the offer for sale (OFS) details.

    Investors considering the Sahajanand Medical Technologies IPO should pay close attention to:

    • Valuation: The IPO valuation will be a critical factor in determining investment attractiveness.
    • Financial Performance: Analyzing the company’s revenue growth, profitability, and debt levels.
    • Competitive Landscape: Understanding how Sahajanand stacks up against its peers in the medical devices market.
    • Regulatory Environment: Keeping abreast of any policy changes that might impact the healthcare sector.
    • Post-IPO Performance: Observing the company’s execution strategy and market reception after listing.

    The Sahajanand Medical Technologies IPO date is eagerly awaited, and the market will be scrutinizing every detail as it unfolds.

    Expert Opinions and Market Sentiment
    Industry analysts and market observers are cautiously optimistic about the Sahajanand Medical Technologies IPO. The company’s strong fundamentals and the inherent growth potential of the medical devices sector are seen as significant positives. However, as with any new IPO, there will be a degree of scrutiny regarding its valuation and the broader market sentiment.

    “Sahajanand Medical Technologies is a well-established player in a crucial segment of healthcare,” commented a market analyst. “Their focus on innovation and their expansion plans, coupled with Ashish Kacholia’s endorsement, makes this an IPO to watch closely. We will be looking at the pricing and the company’s roadmap for growth post-listing.”

    The stock market is always looking for quality companies with a clear growth story, and Sahajanand Medical Technologies appears to fit the bill. The success of this public offering could pave the way for other promising companies in the healthcare and medical technology space to tap the public markets.

    Conclusion: A Promising Future for Sahajanand Medical Technologies
    The impending Sahajanand Medical Technologies IPO marks a significant milestone for the company and a potential opportunity for investors seeking exposure to India’s burgeoning healthcare sector. With its strong product portfolio, robust manufacturing capabilities, and the strategic backing of Ashish Kacholia, Sahajanand is poised for substantial growth. As the company navigates the IPO process, the market will be keenly observing its progress, anticipating the debut of another promising Indian entity on the stock exchanges. The IPO announcement has certainly injected a dose of excitement into the Indian stock market, and many will be holding their breath for the official launch.

    Keywords: Sahajanand Medical Technologies IPO, Ashish Kacholia, Indian IPOs, Medical Devices Market India, Cardiac Stents, IPO News, IPO Filing, DRHP, SEBI, Medical Technology Industry India, IPO Valuation, Fund Raising, IPO Price Band, Indian Stock Market, IPO Process, Public Offering, Upcoming IPO. Data Insights Market

  • Women’s health gets AI support in MP

    Women’s health gets AI support in MP

    In a pioneering move to enhance public healthcare accessibility, the Government of Madhya Pradesh is set to launch SUMAN SAKHI, an AI-powered chatbot aimed at providing vital health information to women—especially during pregnancy—through digital platforms.

    Developed under the leadership of the National Health Mission (NHM), Madhya Pradesh, in collaboration with the Madhya Pradesh State Electronics Development Corporation (MPSeDC) under the Department of Science and Technology, this initiative represents a major step forward in citizen-centric digital governance.

    A virtual assistant for women’s health
    SUMAN SAKHI is designed to serve as a round-the-clock virtual assistant, empowering women with quick and reliable information about government healthcare services, maternal health, high-risk pregnancy factors, and key social welfare schemes. By offering these services in Hindi and operating 24/7, the chatbot is expected to bridge the information gap for beneficiaries across both urban and rural areas.

    “This chatbot is more than just a digital tool—it’s a lifeline for women who need accessible, timely, and accurate health information,” said an NHM official. “With SUMAN SAKHI, we aim to boost awareness, promote preventive healthcare, and ensure no woman is left behind when it comes to government health services.”

    Access via WhatsApp
    To maximise reach and usability, the chatbot will be accessible via WhatsApp, India’s most widely used messaging platform. This approach ensures that even those with basic smartphones can access services without the need for separate apps or complicated platforms.

    Phased rollout with focus on maternal health
    The launch will occur in phases, starting with sectors experiencing the highest demand—such as maternal and reproductive healthcare. Over time, the chatbot’s scope will expand to cover other flagship health and welfare schemes, further strengthening the state’s digital service delivery ecosystem.

    Strengthening governance and transparency
    Officials stated that the initiative is part of a broader vision to improve service delivery, enhance transparency, and build public trust in health governance. By using AI to interact directly with citizens, the government hopes to not only increase service uptake but also reduce dependency on intermediaries.

    “This is a major leap in leveraging technology to support inclusive governance,” added a spokesperson from MPSeDC. “We’re using digital tools to ensure that every woman in Madhya Pradesh can access health information when she needs it most.”

    As SUMAN SAKHI gears up for launch, it reflects Madhya Pradesh’s growing emphasis on digital innovation, women’s health, and public service transformation. With its user-friendly interface, local language support, and focus on priority sectors, the chatbot is poised to become a model for other Indian states seeking to integrate AI into public healthcare delivery. IndiaTV News

  • Neuralink implants reach 12 patients worldwide

    Neuralink implants reach 12 patients worldwide

    Elon Musk’s brain implant company Neuralink said on Tuesday that 12 people worldwide have received its chips.

    This marks an increase from a prior announcement in June, when its partner Barrow Neurological Institute said, opens new tab that seven individuals with severe paralysis had received Neuralink’s implants and were using them to control digital and physical tools through thought.

    Collectively, the patients have had their devices for 2,000 days and accumulated over 15,000 hours of use, Neuralink said on messaging platform X, formerly known as Twitter, on Tuesday.

    In July, Neuralink said it will launch a clinical study in Great Britain to test its chips, partnering with University College London Hospitals and Newcastle Hospitals to conduct the research.

    The company secured $650 million in a funding round in June.

    Neuralink began human trials in 2024 on its brain implant after addressing safety concerns raised by the U.S. Food and Drug Administration, which had initially rejected its application in 2022. Reuters

  • AIIMS Kashmir: Healthcare expansion by 2026

    AIIMS Kashmir: Healthcare expansion by 2026

    Abdullah, who visited the AIIMS site along with health and education minister Sakina Ittoo, said after initial delays in execution of the project, the pace of work has picked up, and the institute is expected to be functional by November next year.

    “The director and the CPWD (officials), who are supervising the works, have assured me that the OPD will be started in March-April next year, which will be followed by starting classes. The IPD (In-Patient Department) is expected to be functional by November- December,” the chief minister told reporters.

    Asked about the delay in the project, Abdullah said the location for the hospital was identified after taking into account various factors, including Army’s concerns.

    “It was not checked whether the site is fit for a hospital. Then there were concerns from the Army about the project. So the detailed project report had to be prepared afresh, and those (Army) concerns were addressed. One year was lost in that.

    “However, now the project work has picked up pace and it will be completed soon,” Abdullah added. PTI

  • New Russian cancer vaccine shows complete efficacy in trials

    New Russian cancer vaccine shows complete efficacy in trials

    In what could mark a turning point in cancer care, Russia has unveiled EnteroMix, a new vaccine reported to show 100 per cent efficacy in early clinical trials.

    Built on technology similar to Covid-19 mRNA vaccines, EnteroMix is said to shrink aggressive tumours, slow their growth, and do so without the harsh side effects of chemotherapy or radiation. Russian health officials claim the shot is safe for repeated use and can be customised to a patient’s individual RNA. The first version targets colorectal cancer, with others in development for glioblastoma and melanoma.

    What does Russia say about the vaccine’s safety and impact?
    “The Russian EnteroMix cancer vaccine is now ready for clinical use,” the Russian Federal Medical and Biological Agency (FMBA) announced.

    FMBA head Veronica Skvortsova said the mRNA-based vaccine had successfully passed preclinical trials, demonstrating both safety and high effectiveness. It showed significant results in shrinking tumours and slowing growth, and was found safe for repeated use. The vaccine will be tailored to each patient’s RNA, making it a fully personalised therapy.

    Skvortsova added that while colorectal cancer is the initial focus, versions are also being developed for glioblastoma—a highly aggressive brain tumour—and specific forms of melanoma, a type of skin cancer.

    The announcement was made via Sputnik, a global wire and digital news service, in a post on X.

    Who developed the EnteroMix cancer vaccine?
    The oncolytic vaccine was developed by the Ministry of Health’s National Medical Research Radiology Centre (NMRRC) in collaboration with the Engelhardt Institute of Molecular Biology under the Russian Academy of Sciences.

    Its public launch took place at the St Petersburg International Economic Forum (SPIEF 2025), where Russia highlighted its latest medical research and biotech breakthroughs.

    How does the vaccine work?
    According to reports, EnteroMix uses a combination of four harmless viruses to target and destroy cancer cells while simultaneously activating the body’s immune defences.

    Following years of preclinical testing, the vaccine has shown the ability to slow tumour progression and, in some cases, eliminate tumours entirely. Phase-1 clinical trials began in June 2025, enrolling 48 volunteers.

    What’s next for EnteroMix?
    With the Phase-1 trial complete and early results described as highly promising, the next step is regulatory clearance. If approved, EnteroMix could become the world’s first personalised cancer vaccine of its kind—delivering a tailored immune response for each patient and potentially reshaping global cancer treatment strategies.

    What are mRNA vaccines and how do they work?
    mRNA vaccines are a new class of vaccines that work by using messenger RNA (mRNA) to teach the body’s immune system how to recognise and fight diseases. Unlike traditional vaccines, which rely on weakened or inactivated germs, mRNA vaccines deliver genetic instructions that tell cells to produce a harmless protein found on the surface of a virus. Once the immune system detects this protein, it learns how to defend against the real virus in the future.

    During Covid-19, this technology enabled scientists to rapidly design vaccines that prevented severe illness and death, making it a game-changer in modern medicine. Importantly, mRNA does not alter human DNA, as it never enters the cell’s nucleus and is naturally broken down within days. With proven safety and effectiveness, researchers are now expanding the use of mRNA vaccines to other diseases, including flu and even personalised cancer treatments. Business Standard